Table III.
Characteristics of AF study populations
| Randomized controlled trials between non–vitamin K anticoagulants and warfarin
|
Contemporary observational registries
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| RE-LY6 (n = 18,113)
|
ROCKET-AF9 (n = 14,264)
|
ARISTOTLE8 (n = 18,201)
|
ENGAGE AF-TIMI 4810 (n = 21,105)
|
GLORIA-AF*34 (n = 56,000)
|
PINNACLE36 (n = 14,464)
|
GARFIELD (cohort 1, n = 10,164)35
|
ORBIT-AF I (n = 10,132)
|
ORBIT-AF II (preliminary, n = 1011)
|
|
| Anticoagulant(s) studied | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | Warfarin, dabigatran | Warfarin | 58% warfarin, 4% non–vitamin K anticoagulant | 72% warfarin, 4% dabigatran | 22% warfarin, 9% dabigatran, 41% rivaroxaban, 14% apixaban |
| Locale | International, including the United States | International, including the United States | United States only | International, excluding the United States | United States only | United States only | |||
| Patient characteristics | |||||||||
| Age (y) | 72 | 73 | 70 | 72 | ≥18 | 67 | 70 | 73 | 73 |
| Female | 36% | 40% | 35% | 38% | N/A | 47% | 43% | 42% | 44% |
| Heart failure | 32% | 62% | 35% | 58% | N/A | 35% | 21% | 32% | 23% |
| Hypertension | 79% | 90% | 87% | 94% | N/A | 70% | 78% | 83% | 83% |
| Diabetes | 23% | 40% | 25% | 36% | N/A | 19% | 22% | 29% | 27% |
| Prior stroke/TIA | 20% | 55% | 20% | 28% | N/A | 3.1% | 14% | 15% | 11% |
| Prior MI | 17% | 17% | 14% | N/A | N/A | 12% | 10% | 16% | 34% |
| New-onset AF | N/A | 1.4% | N/A | N/A | 100% | N/A | 30% | 4.7% | 76% |
| Mean CHADS2 score | 2.1 | 3.5 | 3.5 | 2.8 | N/A | N/A | 1.9 | 2.3 | 2 |
Abbreviations: RELY, Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET-AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thrombo-embolic Events in Atrial Fibrillation; ENGAGE AFTIMI 48, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48; GLORIA-AF, Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation; PINNACLE, Practice Innovation And Clinical Excellence; GARFIELD, Global Anticoagulant Registry in the FIELD; TIA, transient ischemic attack; MI, myocardial infarction; N/A, not applicable.
Data from GLORIA-AF are expected, based on its design.